Here’s What Competition Looks Like In India’s Humira Biosimilars Market

Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.

Leadership
INDIA'S HUMIRA BIOSIMILAR MARKET ALREADY HAS SEVERAL BRANDS VYING FOR SHARE

More from Business

More from Generics Bulletin